| Bioactivity | Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1[1]. |
| Invitro | Balstilimab (AGEN2034) 高亲和力地、选择性地结合 PD-1，并通过阻断 PD-L1 和 PD-L2 与 PD-1 结合从而增强 T 细胞的反应性[1]。 |
| Name | Balstilimab |
| CAS | 2148321-77-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Drouin E E, et al. AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model. Cancer Research, 2017, 77(13_Supplement): 3654-3654. |